FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Назад в Научную Библиотеку
PubMedPreclinical

MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy.

Fu Yu, Tang Mi, Duan Yimei, Pan Yanrong, Liang Min, Yuan Jinghan, Wang Manda, Laher Ismail, Li Shunchang
Biochemical and biophysical research communications2024DOI: 10.1016/j.bbrc.2024.151072
MOTS-c

Качественный Балл

4/10

Цитирования

0

Объекты Исследования

Нечеловеческие

Анализ Peptide Contacts

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.

Findings in Context

These findings advance our understanding of MOTS-c in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Early-stage evidence for MOTS-c. Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.

Ключевые Найденные Результаты

The study found that MOTS-c reduces myocardial inflammation and injury in diabetic rats by inhibiting the ROS/TXNIP/NLRP3 pathway, suggesting a potential therapeutic role for this peptide in treating diabetic cardiomyopathy.

Ограничения

The study is limited to preclinical animal models, which may not fully translate to human clinical settings. Additionally, the specific mechanisms of MOTS-c's action and its long-term efficacy are yet to be determined.

Как интерпретировать эту исследовательскую работу

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Animal model results do not automatically translate to humans. Different species metabolize peptides differently, and dosing does not scale linearly.

4

In vitro (cell culture) studies demonstrate biological mechanisms but cannot account for the complexity of whole-organism physiology.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Цитирование

Fu Yu, Tang Mi, Duan Yimei et al.. (2024). MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy.. Biochemical and biophysical research communications. https://doi.org/10.1016/j.bbrc.2024.151072

Просмотр полного текста на PubMed

Связанные статьи

Исследуйте Дальнейшее

Это содержание основано на рецензированных исследованиях для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.